Gilda Cennamo1, Claudia Rossi2, Maria Angelica Breve2, Nunzio Velotti3, Antonio Farella4, Raffaele Liuzzi5, Giovanni Cennamo2. 1. Eye Clinic, Department of Public Health, University of Naples Federico II, Naples, Italy. xgilda@hotmail.com. 2. Department of Neurosciences, Reproductive Sciences and Dentistry, University of Naples Federico II, Naples, Italy. 3. Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy. 4. Functional and Morphologic Department of Radiotherapy and Legal Medicine, University of Naples "Federico II", Naples, Italy. 5. Institute of Biostructure and Bioimaging, National Research Council (CNR), Naples, Italy.
Abstract
PURPOSE: To describe the vascular changes of circumscribed choroidal hemangioma (CCH) after ruthenium-106 brachytherapy using optical coherence tomography angiography (angio-OCT). METHODS: Seven eyes of 7 patients diagnosed with symptomatic CCH who underwent ruthenium-106 plaque radiotherapy were included in the study. Patients underwent complete ophthalmic examination, bulbar echography and angio-OCT. The same protocol was applied 1 year after ruthenium-106 brachytherapy. RESULTS: At baseline, the mean best-corrected visual acuity (BCVA) in affected eyes was 0.67 ± 0.14 logMAR, and the mean tumor thickness was 4.46 ± 0.91 mm measured by standardized A-scan echography. After ruthenium-106 plaque treatment, the mean BCVA increased to 0.17 ± 0.10 logMAR (p = 0.001) and the mean tumor thickness to 2.29 ± 0.71 mm (p = 0.003). Moreover, there was a significant reduction of the tumor basal diameter (p= 0.009). Intra-tumor angio-OCT measurements revealed a statistically significant reduction of the vessel and flow areas (p = 0.006 and p = 0.002, respectively) 1 year after brachytherapy. CONCLUSIONS: Angio-OCT is a non-invasive reliable method with which to evaluate the vascular features of CCH and consequently to monitor changes after conservative treatment.
PURPOSE: To describe the vascular changes of circumscribed choroidal hemangioma (CCH) after ruthenium-106 brachytherapy using optical coherence tomography angiography (angio-OCT). METHODS: Seven eyes of 7 patients diagnosed with symptomatic CCH who underwent ruthenium-106 plaque radiotherapy were included in the study. Patients underwent complete ophthalmic examination, bulbar echography and angio-OCT. The same protocol was applied 1 year after ruthenium-106 brachytherapy. RESULTS: At baseline, the mean best-corrected visual acuity (BCVA) in affected eyes was 0.67 ± 0.14 logMAR, and the mean tumor thickness was 4.46 ± 0.91 mm measured by standardized A-scan echography. After ruthenium-106 plaque treatment, the mean BCVA increased to 0.17 ± 0.10 logMAR (p = 0.001) and the mean tumor thickness to 2.29 ± 0.71 mm (p = 0.003). Moreover, there was a significant reduction of the tumor basal diameter (p= 0.009). Intra-tumor angio-OCT measurements revealed a statistically significant reduction of the vessel and flow areas (p = 0.006 and p = 0.002, respectively) 1 year after brachytherapy. CONCLUSIONS: Angio-OCT is a non-invasive reliable method with which to evaluate the vascular features of CCH and consequently to monitor changes after conservative treatment.
Authors: Tero Kivelä; Mikko Tenhunen; Timo Joensuu; Petri Tommila; Heikki Joensuu; Mauri Kouri Journal: Ophthalmology Date: 2003-10 Impact factor: 12.079